https://doi.org/10.1053/j.gastro.2013.02.041. PMID: 23470618.

2. Nagata N., Sakurai T., Shimbo T. et al. Acute severe gastrointestinal tract bleeding is associated with an increased risk of thromboembolism and death. Clin Gastroenterol Hepatol. 2017; 15(12): 1882–1889.e1.

https://doi.org/10.1016/j.cgh.2017.06.028. PMID: 28634133.

3. Laursen S.B., Hansen J.M., Hallas J. et al. The excess long-term mortality in peptic ulcer bleeding is explained by nonspecific comorbidity. Scand J Gastroenterol. 2015; 50(2): 145–52.

https://doi.org/10.3109/00365521.2014.992365. PMID: 25540986.

4. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what’s the risk? Aliment Pharmacol Ther. 2006; 24: 897–908.

https://doi.org/10.1111/j.1365-2036.2006.03077.x. PMID: 16948802.

5. Delaney J.A., Opatrny L., Brophy J.M., Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007; 177(4): 347–51.

https://doi.org/10.1503/cmaj.070186. PMID: 17698822. PMCID: PMC1942107.

6. Шахматова О.О., Комаров А.Л., Коробкова В.В. с соавт. Кровотечения из верхних отделов желудочно-кишечного тракта у пациентов со стабильной ишемической болезнью сердца (по результатам проспективного РЕГистра длительной Антитромботической ТерАпии – РЕГАТА). Терапевтический архив. 2020; 92(9): 30–38. (Shakhmatova O.O., Komarov A.L., Korobkova V.V. et al. Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy “REGATТA” results). Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 92(9): 30–38 (In Russ.)).

https://doi.org/10.26442/00403660.2020.09.000699. EDN: XLIIZU.

7. Комаров А.Л., Шахматова О.О., Коробкова В.В. с соавт. Факторы риска и исходы желудочно-кишечных кровотечений у больных стабильной ишемической болезнью сердца: данные наблюдательного регистра длительной антитромботической терапии РЕГАТА-1. Российский кардиологический журнал. 2021; 26(6): 51–60. (Komarov A.L., Shakhmatova O.O., Korobkova V.V. et al. Risk factors and outcomes of gastrointestinal bleeding in patients with stable coronary artery disease: Data from the observational registry of long-term antithrombotic therapy REGATTA-1. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(6): 51–60 (In Russ.)).

https://doi.org/10.15829/1560-4071-2021-4465. EDN: HRVVZO.

8. Freedberg D.E., Kim L.S., Yang Y.X. The Risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017; 152(4): 706–15.

https://doi.org/10.1053/j.gastro.2017.01.031. PMID: 28257716.

9. Xie Y., Bowe B., Li T. et al. Risk of death among users of proton pump inhibitors: A longitudinal observational cohort study of United States veterans. BMJ Open. 2017; 7(6): e015735.

https://doi.org/10.1136/bmjopen-2016-015735. PMID: 28676480. PMCID: PMC5642790.

10. Shiraev T.P., Bullen A. Proton pump inhibitors and cardiovascular events: A systematic review. Heart Lung Circ, 2018; 27(4): 443–50.

https://doi.org/10.1016/j.hlc.2017.10.020. PMID: 29233498.

11. Maggio M., Corsonello A., Ceda G. P. et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013; 173(7): 518–23.

https://doi.org/10.1001/jamainternmed.2013.2851. PMID: 23460307. PMCID: PMC6121698.

12. Tai F.W.D., McAlindon M.E. NSAIDs and the small bowel. Curr Opin Gastroenterol. 2018; 34(3): 175–82.

https://doi.org/10.1097/MOG.0000000000000427. PMID: 29438118.

13. Washio E., Esaki M., Maehata Y. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016; 14(6): 809–815.e1.

https://doi.org/10.1016/j.cgh.2015.10.022. PMID: 26538205.

14. Chen W.C., Lin K.H., Huang Y.T. et al. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther. 2017; 45(12): 1542–50. https://doi.org/10.1111/apt.14079. PMID: 28449186.

15. Tozawa K., Oshima T., Okugawa T. et al. A Randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014; 59(8): 1885–90.

https://doi.org/10.1007/s10620-014-3108-4. PMID: 24659236.

16. Pittayanon R., Piyachaturawat P., Rerknimitr R. et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019; 34(9): 1517–22.

https://doi.org/10.1111/jgh.14671. PMID: 30919492.

17. Takeuchi K., Takayama S., Hashimoto E. et al. Effect of rebamipide on gastric bleeding and ulcerogenic responses induced by aspirin plus clopidogrel under stimulation of acid secretion in rats. J Gastroenterol Hepatol. 2014; 29 (Suppl 4): 37–46.

https://doi.org/10.1111/jgh.12774. PMID: 25521732.

18. Zhang W.T., Wang M.R., Hua G.D. et al. Inhibition of aspirin-induced gastrointestinal injury: Systematic review and network meta-analysis. Front Pharmacol. 2021; 12: 730681.

https://doi.org/10.3389/fphar.2021.730681. PMID: 34475825. PMCID: PMC8406693.

19. Jia R.J., Wang X.-P., Zhang Z.H. et al. Effect of rabeprazole and rebamipide in the treatment of upper gastrointestinal hemorrhage associated with dual antiplatelet therapy in elderly patients with coronary heart disease. Clin Appl Thromb Hemost. 2022; 28: 10760296221130746.

https://doi.org/10.1177/10760296221130746. PMID: 36411982. PMCID: PMC9703470.

20. Gao F., Chen X., Zhang J. Prevalence of gastric and small-intestinal mucosal injury in elderly patients taking enteric-coated aspirin by magnetically controlled capsule endoscopy. Gastroenterol Res Pract.2019: 1582590.

https://doi.org/10.1155/2019/1582590. PMID: 31781185. PMCID: PMC6875337.

21. Tziatzios G., Gkolfakis P., Papanikolaou I. S., Triantafyllou K. Antithrombotic treatment is associated with small-bowel video capsule endoscopy positive findings in obscure gastrointestinal bleeding: A systematic review and meta-analysis. Dig Dis Sci. 2019; 64(1): 15–24.

https://doi.org/10.1007/s10620-018-5292-0. PMID: 30238200.

22. Watanabe T., Sugimori S., Kameda N. et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: A pilot study. Clin Gastroenterol Hepatol. 2008; 6(11): 1279–82.

https://doi.org/10.1016/j.cgh.2008.06.021. PMID: 18995219.

23. Iwamoto J., Mizokami Y., Saito Y. et al. Small-bowel mucosal injuries in low-dose aspirin users with obscure gastrointestinal bleeding. World J Gastroenterol. 2014; 20(36): 13133–38.

https://doi.org/10.3748/wjg.v20.i36.13133. PMID: 25278707. PMCID: PMC4177492.

24. Nishida U., Kato M., Nishida M. et al. Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin. World J Gastroenterol. 2011; 17(2): 226–30.

https://doi.org/10.3748/wjg.v17.i2.226. PMID: 21245996. PMCID: PMC3020377.

25. Mizukami K., Murakami K., Abe T. et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011; 17(46): 5117–22.

https://doi.org/10.3748/wjg.v17.i46.5117. PMID: 22171147. PMCID: PMC3235596.

26. Kurokawa S., Katsuki S., Fujita T. et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014; 49(2): 239–44.

https://doi.org/10.1007/s00535-013-0805-2. PMID: 23595613.

27. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin induced moderate-to-severe small intestinal damage. PLoS One. 2015; 10(4): e0122330.

https://doi.org/10.1371/journal.pone.0122330. PMID: 25874951. PMCID: PMC4398323.

28. Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: A systematic review and meta-analysis. Dig Dis Sci. 2013; 58(7): 1991–2000.

https://doi.org/10.1007/s10620-013-2606-0. PMID: 23456504.

29. Остроумова О.Д., Орлова И.Ю., Кочетков А.И. с соавт. Структура сопутствующих заболеваний органов пищеварения у пациентов, получающих прямые оральные антикоагулянты: результаты многоцентрового кросс-секционного фармакоэпидемиологического исследования. Терапия. 2022; 8(10): 152–161. (Ostroumova O.D., Orlova I.Y., Kochetkov A.I. et al. Structure of concomitant digestive diseases in patients receiving direct oral anticoagulants: Results of a multicenter cross-sectional pharmacoepidemiological study. Terapiya = Therapy. 2022; 8(10): 152–161 (In Russ.)).

https://doi.org/10.18565/therapy.2022.10.152-161. EDN: IDSNZB.

30. Остроумова О.Д., Орлова И.Ю., Кочетков А.И. с соавт. Структура назначения лекарственных препаратов гастропротективного действия у пациентов, получающих прямые оральные антикоагулянты: результаты многоцентрового кросс-секционного фармакоэпидемиологического исследования. Фарматека. 2022; 29(13): 62–69. (Ostroumova O.D., Orlova I.Y., Kochetkov A.I. et al. Structure of prescribing gastroprotective drugs in patients receiving direct oral anticoagulants: Results of a multicenter cross-sectional pharmacoepidemiological study. Farmateka. 2022; 29(13): 62–69 (In Russ.)).

https://doi.org/10.18565/pharmateca.2022.13.62-69. EDN: OCXSAV.

31. Кропачева Е.С., Хакимова М.Б., Кривошеева Е.Н. с соавт. Тяжелые желудочно-кишечные кровотечения у больных с фибрилляцией предсердий, получающих пероральные антикоагулянты (по данным двадцатилетнего наблюдения в рамках РЕГистра длительной Антитромботической ТерАпии – РЕГАТА). Терапевтический архив. 2021; 93(9): 1037–1043. (Kropacheva E.S., Khakimova M.B., Krivosheeva E.N. et al. Severe gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants (based on REGistry of long-term AnTithrombotic TherApy – REGATTA). Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(9): 1037–1043 (In Russ.)).

https://doi.org/10.26442/00403660.2021.09.201019. EDN: IPZEWB.

32. Лазебник Л.Б., Кочетков А.И., Остроумова О.Д. с соавт. Консенсус экспертов по снижению риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Терапия. 2021; 7(10): 23–41. (Lazebnik L.B., Kochetkov A.I., Ostroumova O.D. et al. Experts consensus on reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Terapiya = Therapy. 2021; 7(10): 23–41 (In Russ.)).

https://doi.org/10.18565/therapy.2021.10.23–41. EDN: CSPHUF.

33. Снижение риска желудочно-кишечных кровотечений у пациентов, получающих оральные антикоагулянты. Алгоритмы диагно­стики и лечения. Терапия. 2022; 8(5S): 150–163. (Reducing the risk of gastrointestinal bleeding in patients receiving oral anticoagulants. Algorithms of diagnostic and treatment. Terapiya = Therapy. 2022; 8(5S): 150–163 (In Russ.)).

https://doi.org/10.18565/therapy.2022.5suppl.150-163.